Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 4
2004 5
2005 10
2006 17
2007 37
2008 58
2009 48
2010 45
2011 52
2012 59
2013 56
2014 73
2015 46
2016 64
2017 61
2018 84
2019 79
2020 55
Text availability
Article attribute
Article type
Publication date

Search Results

769 results
Results by year
Filters applied: . Clear all
Page 1
IL-23 in inflammatory bowel diseases and colon cancer.
Neurath MF. Neurath MF. Cytokine Growth Factor Rev. 2019 Feb;45:1-8. doi: 10.1016/j.cytogfr.2018.12.002. Epub 2018 Dec 12. Cytokine Growth Factor Rev. 2019. PMID: 30563755 Review.
Studies in recent years have identified a pivotal role of the cytokine IL-23 in the pathogenesis of inflammatory bowel diseases (IBD: Crohn´s disease, ulcerative colitis) and colitis-associated colon cancer. ...Consistently, neutralizing …
Studies in recent years have identified a pivotal role of the cytokine IL-23 in the pathogenesis of inflammatory bow
Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases.
Bunte K, Beikler T. Bunte K, et al. Int J Mol Sci. 2019 Jul 10;20(14):3394. doi: 10.3390/ijms20143394. Int J Mol Sci. 2019. PMID: 31295952 Free PMC article. Review.
Any dysregulation of this interaction can result in chronic inflammation and autoimmunity and is thought to be a major underlying cause in the initiation and progression of highly prevalent immune-mediated inflammatory diseases (IMIDs) such as psoriasis, rheumatoid …
Any dysregulation of this interaction can result in chronic inflammation and autoimmunity and is thought to be a major underlying cause in t …
Psoriasis and Inflammatory Bowel Disease.
Cottone M, Sapienza C, Macaluso FS, Cannizzaro M. Cottone M, et al. Dig Dis. 2019;37(6):451-457. doi: 10.1159/000500116. Epub 2019 May 10. Dig Dis. 2019. PMID: 31079092 Free article. Review.
BACKGROUND: Inflammatory bowel disease (IBD) and psoriasis (PS) are associated conditions. The reason for this association lies in the sharing of predisposition genes and common immunological mechanisms. ...IBD and PS have in common some comorbidities like ca …
BACKGROUND: Inflammatory bowel disease (IBD) and psoriasis (PS) are associated conditions. The reason for this associat …
Inflammatory bowel disease.
Abraham C, Cho JH. Abraham C, et al. N Engl J Med. 2009 Nov 19;361(21):2066-78. doi: 10.1056/NEJMra0804647. N Engl J Med. 2009. PMID: 19923578 Free PMC article. Review. No abstract available.
Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease.
Wong U, Cross RK. Wong U, et al. Expert Opin Investig Drugs. 2019 May;28(5):473-479. doi: 10.1080/13543784.2019.1597053. Epub 2019 Mar 26. Expert Opin Investig Drugs. 2019. PMID: 30884245 Review.
INTRODUCTION: Blockade of interleukin (IL)-12 and IL-23 is a novel therapeutic target for inflammatory bowel disease (IBD). The monoclonal antibody targeting the shared p40 subunit of IL-12 and IL23, namely ustekinumab, has …
INTRODUCTION: Blockade of interleukin (IL)-12 and IL-23 is a novel therapeutic target for inflammatory
Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders.
Gooderham MJ, Papp KA, Lynde CW. Gooderham MJ, et al. J Eur Acad Dermatol Venereol. 2018 Jul;32(7):1111-1119. doi: 10.1111/jdv.14868. Epub 2018 Mar 9. J Eur Acad Dermatol Venereol. 2018. PMID: 29438576 Free PMC article. Review.
Current clinical paradigms for the treatment of psoriasis have evolved to include targeted biologic therapies, starting with tumour necrosis factor-alpha (TNF-α) inhibitors and later, agents targeting interleukin (IL)-12/23 and IL-17. ...This review wi …
Current clinical paradigms for the treatment of psoriasis have evolved to include targeted biologic therapies, starting with tumour necrosis …
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting.
Moschen AR, Tilg H, Raine T. Moschen AR, et al. Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):185-196. doi: 10.1038/s41575-018-0084-8. Nat Rev Gastroenterol Hepatol. 2019. PMID: 30478416 Review.
Ustekinumab, a therapeutic antibody targeting both cytokines is now widely licensed for the treatment of Crohn's disease, including in Europe, the USA, Canada and Japan, whilst agents targeting IL-23 specifically are in late-phase clinical trials. We review t …
Ustekinumab, a therapeutic antibody targeting both cytokines is now widely licensed for the treatment of Crohn's disease, including i …
Current, experimental, and future treatments in inflammatory bowel disease: a clinical review.
Hvas CL, Bendix M, Dige A, Dahlerup JF, Agnholt J. Hvas CL, et al. Immunopharmacol Immunotoxicol. 2018 Dec;40(6):446-460. doi: 10.1080/08923973.2018.1469144. Epub 2018 May 10. Immunopharmacol Immunotoxicol. 2018. PMID: 29745777 Review.
Inflammatory bowel diseases (IBDs) may result from dysregulated mucosal immune responses directed toward the resident intestinal microbiota. ...These consist of antibodies directed against pro-inflammatory cytokines such as tumor necrosis factor α,
Inflammatory bowel diseases (IBDs) may result from dysregulated mucosal immune responses directed toward the resident i
Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment.
Fragoulis GE, Liava C, Daoussis D, Akriviadis E, Garyfallos A, Dimitroulas T. Fragoulis GE, et al. World J Gastroenterol. 2019 May 14;25(18):2162-2176. doi: 10.3748/wjg.v25.i18.2162. World J Gastroenterol. 2019. PMID: 31143068 Free PMC article. Review.
Extra-articular manifestations, like uveitis, psoriasis and inflammatory bowel disease (IBD) are frequently observed in the setting of SpA and are, in fact, part of the SpA classification criteria. ...Various therapeutic modalities are available with monoclon …
Extra-articular manifestations, like uveitis, psoriasis and inflammatory bowel disease (IBD) are frequently observed in …
Inflammatory bowel disease therapy: blockade of cytokines and cytokine signaling pathways.
Yamamoto-Furusho JK. Yamamoto-Furusho JK. Curr Opin Gastroenterol. 2018 Jul;34(4):187-193. doi: 10.1097/MOG.0000000000000444. Curr Opin Gastroenterol. 2018. PMID: 29846261
PURPOSE OF REVIEW: Treatment of inflammatory bowel disease (IBD) patients can vary depending on the degree of response, lack of response or intolerance to conventional or biological agents aimed at blocking various cytokines or integrins. ...RECENT FINDINGS: …
PURPOSE OF REVIEW: Treatment of inflammatory bowel disease (IBD) patients can vary depending on the degree of response, …
769 results
Jump to page
Feedback